◈ Nootpedia
Compact view
Research pass: medium Peptide · Injectable WATCH-LIST LOW

Humanin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST LOW

Mechanistically interesting endogenous mitochondrial peptide with the longest historical trail of any MDP (discovered 2001, 24+ years of preclinical work) and convergent positive signals across Alzheimer's, ischemia, atherosclerosis, type 2 diabetes, and aging models — but **zero published human RCTs of native Humanin or any analog as of May 2026**. All efficacy evidence sits in cell and rodent work; no analog has reached even Phase 1 in registered trials. The peptide-vendor scene around Humanin is small and quality is questionable. **For Dylan: NOT-ACTIONABLE-YET.** Brain-priority justifies tracking the literature given the Aβ-neuroprotection mechanism, but at 20 with no neurodegenerative target, no human dosing established, and higher-yield V4/V5 brain levers already deployed (Cerebrolysin, citicoline, DHA, modafinil, bromantane, Adamax/Semax), Humanin is a watch-the-pipeline compound, not an experiment-now compound. Would upgrade to OPTIONAL-ADD if (a) any registered Phase 1 opens with safety + biomarker readout, or (b) Cohen lab / independent group publishes a human pharmacokinetic study establishing dosing.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20–30, brain-priority, high cognitive workload + MMA athlete (Dylan-archetype)
    WATCH-LIST

    LOW confidence. Not actionable currently. Mechanism is genuinely interesting for the long-game brain-protection question (cumulative subconcussive impact + decades of cognitive workload + AD risk over 50+ year horizon), but (a) zero human evidence, (b) no subjective signal to confirm action, (c) no commercial biomarker assay, (d) higher-yield brain levers already deployed (Cerebrolysin, citicoline, DHA, modafinil, Adamax/Semax), (e) cost-vs-evidence ratio is poor. Action: track Cohen lab publications and ClinicalTrials.gov annually; revisit verdict if any registered Phase 1 opens.

  • 30–50, executive maintenance
    WATCH-LIST

    LOW confidence. Same logic as 20–30; Humanin is preclinical-only and no current registered trial. Slight increase in interest if family history of AD or early cognitive complaints emerge.

  • 50+, mild cognitive decline / longevity-focused / neurodegeneration concerns
    WATCH-LIST

    → OPTIONAL-ADD (LOW-MEDIUM confidence) in research-aware patients. This is the demographic where the AD-prevention mechanism is most relevant and where the longevity-correlation cohort data points (centenarians, Laron) are most directly applicable. In a comprehensive longevity protocol that already includes MOTS-c, SS-31, NAD+, possibly senolytics, Humanin may be added as the cytoprotective layer of the mitochondrial peptide stack — but with explicit acknowledgment that this is mechanism-driven, not evidence-driven, and biomarker effects are unmeasurable without research-grade assays. Cycle quarterly, accept the experimental nature, drop if any concerning labs emerge.

  • Anxiety-prone
    WATCH-LIST

    No anxiolytic mechanism, no relevant evidence. Theanine, magnesium, behavioral interventions higher-yield.

  • High athletic load, tested status
    WATCH-LIST

    Not currently WADA-banned (unlike MOTS-c since 2024) but the absence of testing infrastructure does not equal absence of risk; if Humanin develops a performance signal in any future trial, WADA could add it. For tested combat athletes: monitor WADA list updates.

  • Sleep-disordered
    WATCH-LIST

    No sleep mechanism, no relevant evidence.

  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST

    Theoretical cytoprotective support, but BPC-157 / TB-500 are higher-yield for direct tissue recovery with much stronger community evidence base.

  • Strength/anabolic-focused
    NEUTRAL

    Wrong category — Humanin is cytoprotective/anti-apoptotic, not anabolic. Not a strength stack inclusion.

  • Active neurodegenerative diagnosis (AD, PD, ALS)
    OPTIONAL-ADD

    with major caveats. This is the indication Humanin was discovered for. In a desperate-clinical-context with conventional treatment failing, mechanism-based experimental use under medical supervision could be considered. Outside that context, the absence of human trial data is the limiting factor.

▸ Subjective experience (deep)

Honest summary across the small number of community reports that exist for chronic Humanin dosing in healthy adults:

  • Acute (per-injection): Nothing. No reported acute energy, cognitive, mood, or sensory effects. This is consistent across the small community report base. Humanin is not subjectively detectable on a per-injection basis the way modafinil, bromantane, or even Cerebrolysin can be.
  • Week 1–4 (chronic dosing 5–25 mg SC weekly to 3×/week): Nothing notable. Some users report "feeling slightly more resilient" or "general well-being" — these descriptions are essentially placebo-floor and indistinguishable from natural week-to-week variation.
  • Week 4–8 (cumulative): Same as 1–4 for most reporters. No characteristic emerging signal. A small fraction of users report "feeling like recovery is slightly better" — again, indistinguishable from training adaptation, sleep variation, or placebo expectation.
  • Cycle off: Effects (such as they are) fade indistinguishably from baseline. No withdrawal, no rebound, no characteristic cessation pattern.

Honesty about variability: Humanin is the most subjectively-quiet compound in this entire wiki for chronic users. This is not necessarily evidence it doesn't work — many anti-aging interventions are biomarker-detectable but not subjectively detectable (statins, metformin, SGLT2 inhibitors, low-dose aspirin) — but it does mean Dylan would have no subjective signal to confirm or deny effect. Decision-making would have to be entirely biomarker-driven, and the relevant biomarkers (plasma Humanin levels, IGFBP-3 axis, possibly cognitive testing if the AD-prevention angle is invoked) are mostly research-grade and not commercially standardized.

Comparison to sister peptide MOTS-c: MOTS-c users at least split ~30–50% report-something / 30–40% report-mild-ambiguous / 15–25% report-nothing. Humanin users skew much further toward the "report-nothing" end of the distribution. Either (a) Humanin's effect is genuinely sub-perceptual in healthy users (consistent with its mechanism — anti-apoptosis is not subjectively detectable in someone whose cells aren't currently dying), or (b) the doses being used in the small community are sub-therapeutic, or (c) the available peptide product is of inconsistent quality.

Injection experience: SC injection (subcutaneous, abdomen or thigh), insulin needle (29–31g × ½"), small volume per dose. Painless, occasional minor injection-site redness. Reconstitute lyophilized vial with bacteriostatic water, refrigerate post-reconstitution, use within 30 days. Injection technique is standard peptide handling.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Unknown. No human pharmacokinetic study has characterized chronic exposure. Conservative cycling is universal vendor convention by analogy to other peptides.
  • Recommended cycle (community convention): 4–8 weeks on, 4–8 weeks off. Quarterly pattern is most common.
  • Reset protocol: No specific reset needed. Peptide half-life is hours; downstream signaling effects fade over 1–4 weeks post-cessation by analogy to other peptides.
  • Long-term cumulative use (years): No data. Theoretical immunogenicity risk over multiple cycles, theoretical IGF-1 axis adaptation. Caution warranted.
▸ Stacking deep dive

Synergistic with

  • mots-c — Sister mitochondrial-derived peptide, complementary mechanism (cytoprotective vs metabolic-signaling). Standard "MDP family stack" pairing. Mechanistic non-overlap is genuine. For Dylan: moot because both are not-currently-actionable, but in a future longevity-protocol context this is a coherent pairing.
  • ss-31 (Elamipretide) — Mitochondrial cardiolipin stabilizer. Different mechanism layer (structural mitochondrial protection vs Humanin's anti-apoptotic signaling). Standard mitochondrial peptide stack triad: Humanin + MOTS-c + SS-31 in longevity protocols, sometimes plus NAD+.
  • nad-plus precursors (NMN / NR / direct NAD+ injection) — Mitochondrial substrate layer. Mechanism-coherent with Humanin's mitochondrial encoding and cytoprotective angle.
  • cerebrolysin — Neurotrophic peptide cocktail (BDNF / GDNF / NGF mimetic activity). Mechanism-different (neurotrophic vs cytoprotective). Theoretical complementarity for AD prevention or neuro-regeneration use cases. For Dylan: Cerebrolysin is in V5 quarterly cycling; Humanin is not. Don't add.
  • semax / adamax — Russian neuropeptides with BDNF-elevation and broad neuroprotective effects. Mechanism-different from Humanin. Theoretical complementarity for cognitive / neuroprotective use. For Dylan: Semax/Adamax in V5 daily; Humanin not added.
  • foxo4-dri — Senolytic. Different aging-biology layer (clears senescent cells vs preserves stressed cells). Both fit longevity-protocol Phase 4 framework for older users. Not load-bearing for Dylan at 20.
  • epithalon — Pineal peptide / putative telomerase activator. Different aging layer. Often paired with mitochondrial peptides in 50+ longevity stacks. Not load-bearing for Dylan at 20.
  • Standard daily V4 / V5 nutrients: DHA, magnesium, citicoline, NAC, PS, etc. — no documented interactions; broadly compatible.

Avoid stacking with

  • Active chemotherapy / radiation oncology treatment — anti-apoptotic mechanism could protect cancer cells. Theoretical, but specifically flagged in oncology peptide reviews.
  • High-dose IGF-1 or GH supplementation — theoretical IGFBP-3 axis interaction; unclear net direction.
  • Other anti-apoptotic peptides without rationale — theoretical redundancy.

Neutral / safe co-administration

  • All V4 daily core supplements (DHA, magnesium, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine/L-tryptophan, D3/K2, beta-alanine, vitamin C)
  • All V5 candidate cognitive compounds (modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, taurine, astaxanthin) — by analogy and absence of documented interaction
  • BPC-157, TB-500 (Dylan's elbow protocol — different mechanism, parallel use OK theoretically)
  • Creatine, electrolytes, standard sports supplementation

Honest framing on stacking: because Humanin has no human pharmacokinetic data, all stacking claims are mechanistic-theoretical, not evidence-based. Treat all "synergistic" claims with appropriate skepticism.

▸ Drug interactions deep dive
  • CYP enzymes: Humanin is a peptide cleared by general peptidases. No significant CYP induction or inhibition documented. Does not affect modafinil (CYP3A4), selegiline (CYP2B6/3A4), bupropion (CYP2B6), or oral contraceptive metabolism.
  • Hormonal contraceptives: No documented interaction (not relevant for Dylan).
  • Anticoagulants: No documented interaction.
  • Alcohol: No specific interaction documented. Dylan is alcohol-free, non-issue.
  • Caffeine: No documented interaction.
  • Insulin / glucose-lowering drugs: Theoretical mild additive effect via IGF-1 axis modulation; clinically minor compared to MOTS-c.
  • Other peptides (BPC-157, TB-500, Cerebrolysin, Semax, MOTS-c): No documented interactions; mechanism layers are largely non-overlapping.
  • GH / IGF-1 supplementation: Theoretical interaction via IGFBP-3 axis. Not relevant for Dylan.
  • AD-targeted drugs (donepezil, memantine, lecanemab, donanemab): Theoretical mechanism-coherent stacking in actual AD treatment context. Not relevant for Dylan currently.
▸ Pharmacogenomics
  • MT-RNR2 mtDNA variants: The Humanin coding region within the 16S rRNA gene contains polymorphisms that could theoretically affect Humanin sequence or expression, but no clinical-scale meta-analysis exists equivalent to the MOTS-c m.1382A>C / K14Q kinesio-genomic finding from the Japanese cohorts. Some Asian-population variants in MT-RNR2 have been associated with longevity in small cohort studies, but the evidence is weaker and less actionable than for MOTS-c.
  • MTRNR2L1-L13 nuclear pseudogene family: The human nuclear genome contains multiple "MT-RNR2-like" pseudogenes (MTRNR2L1 through MTRNR2L13) that produce Humanin-like peptides at varying levels in different tissues. Polymorphisms in these nuclear pseudogenes are an emerging research area; no actionable clinical data yet.
  • For Dylan (Nordic/British ancestry): No specific Humanin-relevant variant currently known to be ancestry-associated for Europeans. Action item post-23andMe (June 2026): when results land, scan for any variants in MT-RNR2 region or MTRNR2L pseudogenes, but expect no actionable findings — the Humanin pharmacogenomic literature is too thin to support specific genotype-driven dosing.
  • No CYP polymorphism relevance (not metabolized by CYPs).
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem (gray-market, US-domestic) Limitless Life (limitlesslifenootropics.com) ~$80–120 / 5 mg vial when in stock medium-high US-made claim, COA on request. Humanin catalog presence is inconsistent — sometimes listed, sometimes out of stock; smaller catalog visibility than MOTS-c.
Research-chem Modern Aminos (modernaminos.com or similar — verify exact vendor) ~$100–150 / 5–10 mg vial medium Mid-tier vendor with broader peptide catalog; Humanin availability variable.
Research-chem Peptide Sciences (peptidesciences.com) ~$130–180 / 5 mg vial medium-high Wider peptide catalog; Humanin listed historically, verify current availability.
Research-chem Core Peptides (corepeptides.com) ~$80–120 / 5 mg vial medium Cheaper end, mixed community reviews on lot consistency.
Research-chem (HNG analog) Various — much rarer than wild-type Humanin ~$150–300 / 5 mg vial low-medium HNG (Gly14-humanin) catalog presence is rare. Quality verification is harder because the analog is synthesized less commonly.
Compounding pharmacy (US, Rx-only) Telehealth peptide clinics Generally not stocked low Humanin is not a routinely-compounded peptide in the US peptide-clinic network as of 2026, distinct from BPC-157, TB-500, MOTS-c, or Semaglutide which have established compounding pathways.
International Russian / Chinese peptide vendors varies low-medium Some Russian peptide vendors (CosmicNootropic etc.) have carried Humanin historically; quality and shipping unpredictable.

Cost math for Dylan (hypothetical, NOT currently recommended):

  • One 4-week experimental cycle at 5 mg SC weekly: 4 × 5 mg = 20 mg total → 4 × 5 mg vials → ~$320–500 per cycle.
  • Quarterly (4 cycles/year): ~$1300–2000/yr. This is substantially over-budget for a WATCH-LIST compound with zero subjective signal, no commercial biomarker assay, and no validated dosing.
  • HNG analog cycles (theoretically lower-dose): harder to source, quality verification harder, marginal cost reduction not guaranteed.

Quality concern: Humanin's smaller commercial market means vendor consistency and COA verification matter more than for MOTS-c. Lot-to-lot purity variation is more likely. Always require:

  • COA: ≥98% purity by HPLC, mass spec confirmation of correct sequence (24-mer for native Humanin, with Gly14 substitution explicitly verified for HNG), endotoxin <0.5 EU/mg
  • Lot number traceable to vendor records
  • Vial integrity, lyophilized cake quality
  • Reconstitution test: dissolves cleanly to clear/colorless solution

Cold chain critical:

  • Lyophilized peptide stable at room temp for shipping (days). Store refrigerated (2–8°C) until reconstitution.
  • Post-reconstitution with bacteriostatic water: refrigerated, use within 30 days.
  • Do NOT freeze reconstituted peptide. Freezing/thawing damages peptide structure.
▸ Biomarkers to track (deep)

Baseline (before any hypothetical first cycle — Dylan is not running this, so this is generic)

  • CBC, CMP, lipid panel, hsCRP, fasting glucose, fasting insulin, HOMA-IR, HbA1c
  • IGF-1, IGFBP-3 — directly relevant to Humanin's IGF-1 axis modulation; track for shifts
  • ALT, AST — hepatic markers
  • MoCA / cognitive baseline — only relevant if AD-prevention is the explicit framing; for Dylan at 20 with no cognitive complaints, MoCA is uninformative (likely 30/30 baseline)
  • Plasma Humanin — research-grade ELISA assay only, not commercially standardized or clinically available as of 2026. Cohen lab has the assay; Quest, LabCorp, and standard commercial labs do not offer it.
  • 23andMe pull (June 2026): scan MT-RNR2 region and MTRNR2L pseudogene variants — likely no actionable findings for Dylan's ancestry

During cycle

  • Subjective log: explicitly track absence of effect (this is informative — if Dylan reports nothing, that matches the prior; if he reports anything strong, that's anomalous and worth investigating)
  • Injection-site reaction log
  • Adverse event log
  • Mid-cycle CMP if cycle exceeds 6 weeks

Post-cycle (4 weeks after stop)

  • Repeat CMP, fasting glucose, fasting insulin, HOMA-IR, HbA1c, lipid panel, ALT, AST
  • Repeat IGF-1, IGFBP-3 — primary Humanin-specific biomarker shift candidate
  • Subjective recap: any cumulative cognitive / recovery signal? (Expected: no.)

Decision rule: because Humanin produces no expected subjective signal and no commercial biomarker assay exists, the decision rule is essentially "is mechanism interesting enough to keep cycling without confirmation?" For Dylan, the answer is no — drop after one cycle if ever run. For a 60+ patient with AD family history and a comprehensive longevity protocol, the answer might be different.

▸ Controversies / open debates Live debate
  • Why has no Humanin program reached Phase 1 in 24 years? This is the single most important open question. Possible explanations:
    • Indication economics: AD trials are extraordinarily expensive and high-failure-rate. The most-validated Humanin indication is also the most-difficult-to-trial indication. Companies may have chosen lower-risk indications (NASH, T2D — where MOTS-c analog CB4211 went) and Humanin's metabolic effects are smaller than MOTS-c's.
    • Pharmacokinetic challenges: the 24-mer peptide may have unfavorable PK (half-life, BBB penetration) for clinically meaningful exposure, especially for CNS indications.
    • IP / commercial: native human peptide sequences are harder to patent; non-native analogs (HNG, colivelin) carry immunogenicity risk; the compositional-IP path may be unclear.
    • Cohen lab publishing pattern: the lab has produced sustained mechanism work but has not partnered with industry to advance to clinical trials at the same pace as the MOTS-c / CohBar / Hudson Biotech path.
    • Quietly in development? Possible some preclinical IND-enabling work exists but is unannounced. No public ClinicalTrials.gov registration as of May 2026 search.
  • HNG potency question. HNG (Gly14-humanin) is reported as ~1000× more potent than wild-type Humanin in cell-culture Aβ-rescue assays. Whether this translates to a 1000× dose-reduction in vivo, or a much smaller potency multiplier (10×, 100×), is unknown. No comparative human PK study exists. Vendor protocols often suggest HNG at doses 1/5 to 1/10 of wild-type Humanin doses, which is far below the cell-culture potency multiplier — this implicitly assumes the in vivo multiplier is much smaller. Whether even that lower dose is therapeutically meaningful is unknown.
  • Humanin as "longevity peptide" — overstated? The marketing framing rests on (a) plasma Humanin declining with age in humans, (b) centenarians showing preserved levels, (c) Laron mice and humans showing elevated levels with extended longevity. All three are correlational. No interventional human longevity data exists. The "longevity peptide" framing significantly outpaces evidence; for vendor marketing this is standard, but for honest assessment Humanin is a mechanistically-promising candidate longevity peptide, not a validated one.
  • Cohen lab concentration risk. A substantial fraction of Humanin primary mechanism work comes from Cohen / Lee at USC. Independent labs (Hashimoto continued some work, multiple AD model labs, vascular biology labs) have produced positive data, but the lab-concentration is similar to early-stage MOTS-c and represents a real replication-scaling gap.
  • AD trial implications: lecanemab / donanemab era. With Aβ-targeting monoclonals (lecanemab, donanemab) having achieved FDA approval in 2023–2024 with modest cognitive-decline slowing in early AD, the bar for any new AD-relevant therapeutic is higher. Humanin would need to demonstrate either equivalent / superior Aβ effects or address a non-Aβ pathology (tau, neuroinflammation, mitochondrial dysfunction). Mechanism allows for the latter framing but no preclinical-to-clinical bridge has been built.
  • Verdict-confidence honesty. I am marking this WATCH-LIST, LOW confidence because:
    • Mechanism is genuinely interesting and well-characterized over 24 years.
    • Zero human RCT data, zero registered Phase 1 trials.
    • No subjective signal to confirm pharmacological action.
    • No commercial biomarker assay.
    • No vendor-validated dosing.
    • Smaller and more inconsistent peptide-vendor catalog than MOTS-c.
    • Higher-yield brain levers already in Dylan's V4/V5 stack.
    • What would change verdict to OPTIONAL-ADD: (a) any registered Phase 1 opens, (b) Cohen lab or independent group publishes a human PK / single-ascending-dose study, (c) commercial plasma Humanin assay becomes available enabling pharmacological-action confirmation.
    • What would change verdict to STRONG-CANDIDATE: Phase 2 readout with positive cognitive or biomarker signal in any indication.
    • What would change verdict to SKIP: safety signal in any future Phase 1, or definitive demonstration that 24-mer peripheral Humanin doesn't reach CNS in pharmacologically-meaningful concentrations.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: WATCH-LIST (LOW confidence). Humanin is the founding mitochondrial-derived peptide (Hashimoto / Nishimoto 2001), discovered specifically as an Alzheimer's-rescue factor from cDNA library of the AD-resistant occipital cortex. Mechanism is multi-pathway and well-characterized over 24 years: extracellular FPR2/CNTFR/gp130 → STAT3 anti-apoptotic signaling, direct Bax / tBid antagonism at the mitochondrial outer membrane, IGFBP-3 axis modulation, direct Aβ neutralization. HNG (Gly14-humanin) is ~1000× more potent than wild-type in cell-culture Aβ-rescue assays. Convergent positive rodent / cell signals across AD, ischemia, atherosclerosis, T2D, aging models. Plasma Humanin declines with age in humans; centenarians and Laron-mice/humans show elevated levels. Zero human RCTs, zero registered Phase 1 trials in ClinicalTrials.gov / EU CTR / WHO ICTRP as of May 2026 — Humanin is a generation behind sister peptide MOTS-c in clinical translation despite being older and better-characterized. Sister peptide context: Humanin (cytoprotective / anti-apoptotic / neuroprotective) and MOTS-c (metabolic-signaling / exercise-mimetic) are the two most-characterized members of a broader MDP family that includes the SHLP1-6 series and SS-31. For Dylan (20yo MMA athlete, brain-priority co-equal #1): mechanism is genuinely interesting for the long-game brain-protection question, but (a) zero human evidence, (b) no subjective signal, (c) no commercial biomarker assay, (d) higher-yield V4/V5 brain levers already deployed (Cerebrolysin quarterly, citicoline daily, DHA daily, modafinil + bromantane + Adamax/Semax in V5), (e) peptide-vendor scene small with quality variable, (f) cost ~$1300–2000/yr quarterly is substantial for a no-evidence compound. Action: WATCH-LIST. Track Cohen lab publications + ClinicalTrials.gov annually. Revisit verdict if any registered Phase 1 opens. For 50+ users in a comprehensive longevity protocol, Humanin sits at OPTIONAL-ADD as the cytoprotective layer of a mitochondrial peptide stack (with MOTS-c, SS-31, NAD+) — but Dylan is not in that demographic.
▸ Open questions / gaps Open
  1. Will any Humanin or HNG program reach Phase 1 by 2030? The 24-year preclinical-only duration is a yellow flag. Track ClinicalTrials.gov, EU CTR, WHO ICTRP annually under "humanin," "HNG," "S14G-humanin," "colivelin," "MTRNR2L1-derived peptide."
  2. Cohen lab next steps. USC Leonard Davis School of Gerontology continues Humanin and broader MDP work. Watch for any partnership announcements, IND filings, or analog-development papers.
  3. Commercial plasma Humanin assay availability. Currently research-grade only. If a clinical-grade ELISA emerges, Humanin becomes more biomarker-trackable.
  4. HNG in vivo potency multiplier. The 1000× cell-culture potency advantage has never been validated in human or even rodent peripheral pharmacology. This determines whether HNG vendor protocols (lower doses) are sub-therapeutic or appropriate.
  5. BBB penetration of 24-mer Humanin after peripheral SC injection. Critical for any CNS / AD / neuroprotection use case. ICV and intranasal rodent data is convincing; peripheral SC bypass to CNS is unclear.
  6. Long-term immunogenicity of repeated cycles, especially for HNG (non-native sequence).
  7. Cancer interaction profile. Anti-apoptotic mechanism creates theoretical concern in active malignancy; pro / anti-tumor signals in cancer models are mixed. Needs better characterization before widespread use.
  8. Combat-athlete-specific endpoints. No targeted study, no community evidence base. The hypothetical "Humanin for long-term subconcussive-impact protection" use case is mechanistically defensible but completely unsupported by evidence.
  9. Mitochondrial peptide stack synergy data. "MOTS-c + Humanin + SS-31" is a marketing-driven longevity stack with no controlled comparison data. Mechanism-coherent; evidence-thin.
  10. Whether Humanin's 24-year preclinical-only status is a "haven't gotten around to it" or a "tried and failed quietly." No public information exists either way.
▸ Sources (full, with our context)
Back to compact view